Differential diagnostic value of tumor markers and contrast-enhanced computed tomography in gastric hepatoid adenocarcinoma and gastric adenocarcinoma

ObjectiveThis study aimed to investigate the effectiveness of tumor markers and contrast-enhanced computed tomography (CE-CT) in differentiating gastric hepatoid adenocarcinoma (GHA) from gastric adenocarcinoma (GA).MethodsThis retrospective study included 160 patients (44 with GHA vs. 116 with GA)...

Full description

Bibliographic Details
Main Authors: Congsong Dong, Yanling Wang, Xiaoyu Gu, Xiaojing Lv, Shuai Ren, Zhongqiu Wang, Zhenyu Dai
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-07-01
Series:Frontiers in Oncology
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2023.1222853/full
_version_ 1797777326159691776
author Congsong Dong
Yanling Wang
Xiaoyu Gu
Xiaojing Lv
Shuai Ren
Zhongqiu Wang
Zhenyu Dai
author_facet Congsong Dong
Yanling Wang
Xiaoyu Gu
Xiaojing Lv
Shuai Ren
Zhongqiu Wang
Zhenyu Dai
author_sort Congsong Dong
collection DOAJ
description ObjectiveThis study aimed to investigate the effectiveness of tumor markers and contrast-enhanced computed tomography (CE-CT) in differentiating gastric hepatoid adenocarcinoma (GHA) from gastric adenocarcinoma (GA).MethodsThis retrospective study included 160 patients (44 with GHA vs. 116 with GA) who underwent preoperative CE-CT. Preoperative serum concentrations of tumor biomarkers and CT imaging features were analyzed, including alpha-fetoprotein (AFP), carcinoembryonic antigen (CEA), carbohydrate antigen 19-9 (CA19-9), carbohydrate antigen 125 (CA125), tumor location, growth pattern, size, enhancement pattern, cystic changes, and mass contrast enhancement. Multivariate logistic regression analyses were performed to evaluate useful tumor markers and CT imaging features for differentiating GHA from GA.ResultsWhen compared to GA, GHA showed a higher serum AFP [13.27 ng/ml (5.2–340.1) vs. 2.7 ng/ml (2.2–3.98), P <0.001] and CEA levels [4.07 ng/ml (2.73–12.53) vs. 2.42 ng/ml (1.38–4.31), P <0.001]. CT imaging showed GHA with a higher frequency of tumor location in the gastric antrum (P <0.001). GHA had significantly lower attenuation values at the portal venous phase [PCA, (82.34 HU ± 8.46 vs. 91.02 HU ± 10.62, P <0.001)] and delayed phase [DCA, (72.89 HU ± 8.83 vs. 78.27 HU ± 9.51, P <0.001)] when compared with GA. Multivariate logistic regression analyses revealed that tumor location, PCA, and serum AFP level were independent predictors of differentiation between GHA and GA. The combination of these three predictors performed well in discriminating GHA from GA, with an AUC of 0.903, a sensitivity of 86.36%, and a specificity of 81.90%.ConclusionsIntegrated evaluation of tumor markers and CT features, including tumor location, PCA, and serum AFP, allowed for more accurate differentiation of GHA from GA.
first_indexed 2024-03-12T23:02:29Z
format Article
id doaj.art-24b9ac87a9b54040b950eaa70b1bb8e8
institution Directory Open Access Journal
issn 2234-943X
language English
last_indexed 2024-03-12T23:02:29Z
publishDate 2023-07-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Oncology
spelling doaj.art-24b9ac87a9b54040b950eaa70b1bb8e82023-07-19T08:26:23ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2023-07-011310.3389/fonc.2023.12228531222853Differential diagnostic value of tumor markers and contrast-enhanced computed tomography in gastric hepatoid adenocarcinoma and gastric adenocarcinomaCongsong Dong0Yanling Wang1Xiaoyu Gu2Xiaojing Lv3Shuai Ren4Zhongqiu Wang5Zhenyu Dai6Department of Radiology, Affiliated Hospital 6 of Nantong University (Yancheng Third People’s Hospital), Yancheng, ChinaDepartment of Radiology, The People’s Hospital of Suzhou New District, Suzhou, ChinaDepartment of Radiology, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, ChinaDepartment of Radiology, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, ChinaDepartment of Radiology, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, ChinaDepartment of Radiology, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, ChinaDepartment of Radiology, Affiliated Hospital 6 of Nantong University (Yancheng Third People’s Hospital), Yancheng, ChinaObjectiveThis study aimed to investigate the effectiveness of tumor markers and contrast-enhanced computed tomography (CE-CT) in differentiating gastric hepatoid adenocarcinoma (GHA) from gastric adenocarcinoma (GA).MethodsThis retrospective study included 160 patients (44 with GHA vs. 116 with GA) who underwent preoperative CE-CT. Preoperative serum concentrations of tumor biomarkers and CT imaging features were analyzed, including alpha-fetoprotein (AFP), carcinoembryonic antigen (CEA), carbohydrate antigen 19-9 (CA19-9), carbohydrate antigen 125 (CA125), tumor location, growth pattern, size, enhancement pattern, cystic changes, and mass contrast enhancement. Multivariate logistic regression analyses were performed to evaluate useful tumor markers and CT imaging features for differentiating GHA from GA.ResultsWhen compared to GA, GHA showed a higher serum AFP [13.27 ng/ml (5.2–340.1) vs. 2.7 ng/ml (2.2–3.98), P <0.001] and CEA levels [4.07 ng/ml (2.73–12.53) vs. 2.42 ng/ml (1.38–4.31), P <0.001]. CT imaging showed GHA with a higher frequency of tumor location in the gastric antrum (P <0.001). GHA had significantly lower attenuation values at the portal venous phase [PCA, (82.34 HU ± 8.46 vs. 91.02 HU ± 10.62, P <0.001)] and delayed phase [DCA, (72.89 HU ± 8.83 vs. 78.27 HU ± 9.51, P <0.001)] when compared with GA. Multivariate logistic regression analyses revealed that tumor location, PCA, and serum AFP level were independent predictors of differentiation between GHA and GA. The combination of these three predictors performed well in discriminating GHA from GA, with an AUC of 0.903, a sensitivity of 86.36%, and a specificity of 81.90%.ConclusionsIntegrated evaluation of tumor markers and CT features, including tumor location, PCA, and serum AFP, allowed for more accurate differentiation of GHA from GA.https://www.frontiersin.org/articles/10.3389/fonc.2023.1222853/fullgastric cancerhepatoid adenocarcinomaα-fetoprotein (AFP)computed tomographydifferential diagnosis
spellingShingle Congsong Dong
Yanling Wang
Xiaoyu Gu
Xiaojing Lv
Shuai Ren
Zhongqiu Wang
Zhenyu Dai
Differential diagnostic value of tumor markers and contrast-enhanced computed tomography in gastric hepatoid adenocarcinoma and gastric adenocarcinoma
Frontiers in Oncology
gastric cancer
hepatoid adenocarcinoma
α-fetoprotein (AFP)
computed tomography
differential diagnosis
title Differential diagnostic value of tumor markers and contrast-enhanced computed tomography in gastric hepatoid adenocarcinoma and gastric adenocarcinoma
title_full Differential diagnostic value of tumor markers and contrast-enhanced computed tomography in gastric hepatoid adenocarcinoma and gastric adenocarcinoma
title_fullStr Differential diagnostic value of tumor markers and contrast-enhanced computed tomography in gastric hepatoid adenocarcinoma and gastric adenocarcinoma
title_full_unstemmed Differential diagnostic value of tumor markers and contrast-enhanced computed tomography in gastric hepatoid adenocarcinoma and gastric adenocarcinoma
title_short Differential diagnostic value of tumor markers and contrast-enhanced computed tomography in gastric hepatoid adenocarcinoma and gastric adenocarcinoma
title_sort differential diagnostic value of tumor markers and contrast enhanced computed tomography in gastric hepatoid adenocarcinoma and gastric adenocarcinoma
topic gastric cancer
hepatoid adenocarcinoma
α-fetoprotein (AFP)
computed tomography
differential diagnosis
url https://www.frontiersin.org/articles/10.3389/fonc.2023.1222853/full
work_keys_str_mv AT congsongdong differentialdiagnosticvalueoftumormarkersandcontrastenhancedcomputedtomographyingastrichepatoidadenocarcinomaandgastricadenocarcinoma
AT yanlingwang differentialdiagnosticvalueoftumormarkersandcontrastenhancedcomputedtomographyingastrichepatoidadenocarcinomaandgastricadenocarcinoma
AT xiaoyugu differentialdiagnosticvalueoftumormarkersandcontrastenhancedcomputedtomographyingastrichepatoidadenocarcinomaandgastricadenocarcinoma
AT xiaojinglv differentialdiagnosticvalueoftumormarkersandcontrastenhancedcomputedtomographyingastrichepatoidadenocarcinomaandgastricadenocarcinoma
AT shuairen differentialdiagnosticvalueoftumormarkersandcontrastenhancedcomputedtomographyingastrichepatoidadenocarcinomaandgastricadenocarcinoma
AT zhongqiuwang differentialdiagnosticvalueoftumormarkersandcontrastenhancedcomputedtomographyingastrichepatoidadenocarcinomaandgastricadenocarcinoma
AT zhenyudai differentialdiagnosticvalueoftumormarkersandcontrastenhancedcomputedtomographyingastrichepatoidadenocarcinomaandgastricadenocarcinoma